No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Press Release: Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
Bernstein Adjusts Price Target on Insulet to $315 From $305, Keeps Outperform Rating
Bernstein Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $315
Bernstein Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $305
Diabetes Device Maker Beta Bionics Files for $100M IPO
Citi Says 'Buy' These Stocks in '25; SA Quant Ratings Says Maybe Not